Wearable Patch Tracks Silent Heart Injury After Surgery
A wearable patch built by researchers at McMaster University, the University of Waterloo and NYU Tandon continuously tracks cardiac troponin I through the skin and followed the protein's rise and fall in mice, according to a study published in Science Advances on November 18, 2026. The work is preclinical, the device has not been tested in surgical patients, and about 90 percent of heart injuries after noncardiac surgery currently pass without symptoms.
Edited and fact-checked by Stephen Sprague
Every result so far comes from animal testing, and human studies have not yet run.
A patient can feel fine after surgery while heart muscle quietly takes damage, and co-author Bernardo Trigatti put that problem in one line. Trigatti is a professor in McMaster's Department of Biochemistry and Biomedical Sciences, and he studies the injury patients never feel. "After surgery, a patient can feel fine even when the heart muscle has been injured," Trigatti said. The injury has a name, myocardial injury after noncardiac surgery, and it reaches about 20 percent of higher-risk patients in the days after an operation that never touched the heart.
About 300 million people undergo noncardiac surgery each year, and more of them go home the same day, which is exactly when the risk window opens, and Leyla Soleymani described why the cases stay hidden. Soleymani is a professor of engineering physics at McMaster, and she led the engineering side of the project. "About 90% of these cases are silent. The only way to diagnose many of them is through a blood test, which is difficult when patients are already home," she said. "We wanted to develop a way to continuously monitor for heart injuries without requiring repeated blood draws."
The patch answers that problem with microscopic polymer needles that penetrate just beneath the skin and stop short of nerves and blood vessels, and the needles collect interstitial fluid, the liquid that surrounds cells. They deliver that fluid to a biosensor that tracks cardiac troponin I, the protein heart muscle releases when it is injured, and proteins are far harder to follow than glucose. Troponin circulates at very low concentrations and arrives even more diluted under the skin, so the team combined antibodies, which recognize the protein, with aptamers, short DNA strands that generate the measurable signal.
In mice, the patch followed the same rise and fall of troponin that blood samples showed after an injection, and it detected elevated levels in animals with coronary artery disease, the NYU Tandon team reported, and Mahla Poudineh's group built the sampling layer. Poudineh is an associate professor at NYU Tandon whose group pioneered the polymeric microneedles, and she led the Waterloo work that made continuous sampling possible. "In mice, the patch followed the same rise and fall we saw in blood samples," Soleymani said. "One of the next questions is how quickly a change in the blood shows up in the fluid under the skin."
That open question marks the boundary of what the study proves, because every result so far comes from animal testing rather than from patients recovering at home, and the team plans further testing. The researchers are pursuing commercialization through Aptec Health, a startup co-founded by Poudineh and Soleymani, and how early the patch could flag an injury in a person remains unanswered. How fast a blood change surfaces in skin fluid is also unknown until human studies run.
Sources
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.